PCV48 Systematic Review of Cost-Effectiveness Models for Pharmacologic Stroke Prevention in Atrial Fibrillation

  • Limone B
  • Baker W
  • Roberts M
  • et al.
Citations of this article
Mendeley users who have this article in their library.


OBJECTIVES: To conduct a systematic review of economic models of pharmacologic stroke prevention in atrial fibrillation (SPAF). METHODS: We searched Medline, Embase, NHSEED and the Tuft,s Registry through May 2012. Included models assessed pharmacologic SPAF using a Markov process or discrete event simulation (DES), calculated both costs and effectiveness, and was published in English. Two investigators independently screened models and extracted data. RESULTS: Twenty- two models, published between 1995 and 2012, were identified. One model was a DES, and the remainder Markov models. Eleven models used a structure similar to Gage et al. (1995); five were derivatives of Sorensen et al. (2009), with the remainder using unique structures. Only 5 models had a non-CNS systemic embolism health state. Models typically started at 65 or 70 years and followed patients for their lifetime (e.g., ≥75 years of age). Inaccuracies in reporting of perspective existed; however, no model included indirect costs and all but one calculated qualityadjusted life-years (QALYs). Twenty models included warfarin; however, only 50% assessed the impact of INR control on conclusions. Most models included aspirin alone (73%), ten evaluated newer anticoagulants, and three evaluated clopidogrel+aspirin. Comparative efficacy and safety data for warfarin vs. aspirin/ control models were often derived from meta-analyses; whereas, data for newer agents came from a lone randomized trial. Models otherwise used similar sources of non-drug dependent inputs. Eighty-two percent of reported base-case incremental cost-effectiveness ratios (ICERs) were cost-effective (<$50,000/QALY). Models typically found warfarin (vs. aspirin/no therapy), dabigatran and rivaroxaban (vs. warfarin), and apixaban (vs. aspirin) to be cost-effective; data on clopidogrel+aspirin (vs. aspirin) to be conflicting, and genotyped-warfarin and ximelagtran not cost-effective. CONCLUSIONS: Cost-effectiveness models of pharmacologic SPAF have been extensively published; but none have estimated the comparative cost-effectiveness of newer agents. Models used similar structures and non-drug-specific inputs, and commonly find innovator strategies to be cost-effective.




Limone, B., Baker, W. L., Roberts, M., & Coleman, C. I. (2012). PCV48 Systematic Review of Cost-Effectiveness Models for Pharmacologic Stroke Prevention in Atrial Fibrillation. Value in Health, 15(7), A370–A371. https://doi.org/10.1016/j.jval.2012.08.991

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free